With deep molecular insights from a simple blood sample, Caris Assure™ offers a minimally-invasive option for biomarker analysis and serial monitoring of cancer patients when tissue samples are not available. No matter the specimen type – tissue or blood – Caris Life Sciences’ flexible, multi-faceted molecular profiling platforms deliver uncompromising reliability to guide personalized treatment decisions and improve patient outcomes.*
Novel cNAS Approach
Circulating Nucleic Acid Sequencing
(cfDNA, cfRNA, gDNA, gRNA)
Whole Exome Sequencing (WES) DNA
SNV INDEL CNA
Whole Transcriptome Sequencing (WTS) RNA
Fusion Variant Transcript
22,000 Gene Coverage
Somatic Tumor Somatic CHIP
MSI TMB LOH
Caris Assure blood-based profiling will be available in summer/fall of 2022, with expanded availability in 2023. Not available in all locations.
The online form below is intended for healthcare professionals only. Sign up to get updates on Caris Assure features and availability. If you are a patient, please contact your doctor for more information about Caris Assure.
* Caris Assure is intended for patients with previously diagnosed solid malignant neoplasms where tissue is not available, or the diagnostic specimen has been exhausted, and is to be used by qualified healthcare professionals. Subject to availability. Not available in all locations.
† Not a replacement for comprehensive germline testing. Incidental pathogenic alterations detected in ACMG recognized cancer genes are reported. Negative results do not imply the patient does not harbor a germline mutation.